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A 10-year follow-up of a randomized study with methyiprednisolone
and chiorambucil in membranous nephropathy. The natural course of
idiopathic membranous nephropathy is variable, with some patients slowly
progressing to renal failure while others maintain normal renal function
over the entire time. Whether to treat this disease or not is controversial
due to the lack of controlled data about the long-term effects of treatment.
We updated at 10 years the results of a controlled trial in which 81 patients
with idiopathic membranous nephropathy and nephrotic syndrome were
randomly assigned to receive symptomatic therapy (39 patients) or a
treatment of six months with methylprednisolone and chlorambucil (42
patients). The probability of surviving without developing end-stage renal
disease at 10 years was 92% in patients given methylprednisolone and
chiorambucil versus 60% in controls (P = 0.0038). The slope of the
reciprocal of plasma creatinine up to 10 years was significantly better in
treated patients than in controls (P = 0.035). The probability of having a
complete or partial remission of the nephrotic syndrome was significantly
higher in treated patients (P = 0.000). Patients assigned to therapy spent
significantly longer time without nephrotic syndrome than untreated
patients (P = 0.0001). Four patients had to stop treatment because of
reversible side-effects. In the long-term one treated patient developed
diabetes and another one became obese. In conclusion, a six-month
therapy with methylprednisolone and chlorambucil increases the proba-
bility of remission of proteinuria and protects from renal function
deterioration even in the long-term. This treatment may avoid dialysis or
death within 10 years to about one third of nephrotic patients with
membranous nephropathy.
Idiopathic membranous nephropathy is an immune-complex
mediated renal disease which is usually associated with the
nephrotic syndrome. The course of the disease is variable. Some
patients maintain normal kidney function with or without a
spontaneous remission of proteinuria, while others progress to
end-stage renal failure or die from complications related to the
nephrotic syndrome. Unfortunately, the long-term outcome for
each patient is difficult to predict at clinical onset, but severe
proteinuria [1], elevated serum creatinine [1], or interstitial fibro-
sis at renal biopsy [2] are frequently associated with a poor
prognosis. Whether or not to treat a patient with idiopathic
membranous nephropathy is still controversial. Some controlled
trials reported beneficial effects of corticosteroids [3] or of
cytotoxic drugs [4—6], but other randomized studies failed to show
favorable results with these agents [7—9].
In 1984 [10] we published the results of a controlled study
where patients with idiopathic membranous nephropathy and
nephrotic syndrome were randomized to receive supportive ther-
apy or to be given a six month therapy with methyiprednisolone
and chlorambucil alternated every other month. After a median
follow up of five years, treated patients had more remissions of the
nephrotic syndrome and showed a better slope of the reciprocal of
plasma creatinine than untreated controls [11]. A decision anal-
ysis based on the data at five years confirmed a better quality-
adjusted life expectancy for patients randomized to be given
combined treatment [121. A limitation of these studies was the
relatively short follow up, while the disease usually runs a slowly
progressive course. Therefore, to predict the long-term renal
outcome we had to use indirect measures such as the slope of the
reciprocal of plasma creatinine, instead of primary end points,
such as dialysis or death. On the other hand, some disquieting side
effects of chlorambucil may develop in the long-term. Since we
continued to follow the patients admitted to this study, we thought
interesting to reanalyze the results at 10 years.
Methods
Patients
Between 1976 and 1983, 81 nephrotic adults with idiopathic
membranous nephropathy were randomly assigned to be treated
with methyiprednisolone plus chlorambucil (42 patients) or with
symptomatic therapy (39 patients). Criteria for admission and
exclusion have been reported elsewhere [10, 11].
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Treatment consisted of 1 g intravenous methylprednisolone
given every 24 hours for three consecutive days, followed by oral
prednisone at a dose of 0.5 mg/kg/day in a single morning
administration for 27 days (Cycle A). After the first month
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prednisone was stopped and the patient was given chiorambucil,
0.2 mg/kg/day for one month (Cycle B). Cycle A and B were
repeated three times so that the whole treatment lasted six
months, three with corticosteroids and three with chiorambucil.
The clinicians were free to give a new course of methyipred-
nisolone and chiorambucil to patients randomized to treatment
only after at least two years from the first treatment.
Response criteria
Complete remission was defined as a reduction of urinary
protein excretion to 0.2 g or less per day. Partial remission was
defined by a daily urinary protein excretion between 0.21 and 2 g
with normal plasma creatinine. Renal dysfunction was defined as
an increase in the plasma creatinine concentration of at least 50%
over the baseline value.
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The cumulative probability of clinical event (death/dialysis or
complete/partial remission for two separate analyses) was esti-
mated according to Kaplan and Meier [13]; comparisons between
strata were made with the generalized Wilcoxon test [14]. The
analysis was truncated at 10 years in order to have a sufficient
number of events for a reliable estimate of the cumulative
probability. An index of efficacy was calculated for each patient as
the percentage of the remission time, that is:
months in remission
x 100
total months of follow up
Then the two treatments were compared by the Wilcoxon test.
The reciprocal of the plasma creatinine values for the two
treatments were compared by mixed-factorial analysis of variance
for repeated measurements [15] with the treatment as a fixed
"between patient" factor at two levels and time as a fixed "within
patient" factor at twenty-one levels (every 6 months). The Geis-
ser-Greenhouse [16] procedure of the the correction of the
degrees of freedom for the statistical significance of the within
patient terms was followed.
Patients who did not complete treatment were included in the
analysis according to the intention-to-treat principle. For the four
patients who died and the 19 who were lost to follow-up, data
obtained at the last observation were considered.
Results
As already reported [10, 11], at presentation the treated and the
control groups were similar in age, sex, duration of the disease,
mean plasma creatinine, mean urinary protein excretion, preva-
lence of hypertension, as well as for distribution of glomerular
stages, and frequency and severity of vascular and tubulointersti-
tial lesions at renal biopsy. All patients assigned to treatment
completed the six months of therapy with the exception of four
patients who stopped treatment earlier because of side effects (see
later). Ten controls and nine treated patients were lost to
follow-up from 12 to 96 months after randomization. The data
available at the last observation and the events that occurred
including endpoints, were considered for analysis. Two controls,
one still nephrotic and the other one with renal function deteri-
oration asked to be treated because of the deterioration of renal
function and then were lost to follow-up 22 and 28 months after
randomization with unchanged clinical conditions.
Three control patients died. Death was always considered as the
end point. A 68-year-old man with persisting nephrotic syndrome
and progressive renal insufficiency died of cardiac infarct two
years after admission. A 54-year-old woman had viral hepatitis
and died of hepato-renal failure 40 months after randomization.
A 31-year-old man with persisting nephrotic syndrome and slowly
progressive renal insufficiency developed a progressive respiratory
insufficiency and suddenly died of cardiorespiratoiy arrest, 90
months after randomization. One treated patient died of cancer
two years after randomization. This 51-year-old man had been a
heavy smoker. He was recognized to have a lung cancer 18 months
after completing treatment.
Nine control and two treated patients had to be submitted to
regular dialysis. The probability of being alive with kidney func-
tioning at 10 years was 0.92 (range 0.83 to 1.00), 95% confidence
interval (CI), for treated patients versus 0.60 (0.42 to 0.78), 95%
CI for untreated controls (Fig. 1), the difference being statistically
significant (P = 0.0038).
We evaluated the slopes of the mean reciprocal of plasma
creatinine for patients followed for 10 years. We assigned an
arbitrary level of plasma creatinine of 10 mg/dl (880 mol/liter) to
patients on maintenance dialysis. After 10 years the mean recip-
rocal of plasma creatinine as expressed in mg/dl reduced from
1.00 to 0.51 in the control group and from 1.01 to 0.84 in the
treated group. The difference between the two slopes was signif-
icant (P = 0.035). Of interest, the slope of the reciprocal of
plasma creatinine significantly dropped in the control group since
the 12th month. Instead the slope tended to remain stable in
treated patients until the 90th month and then reduced signifi-
cantly (Fig. 2).
During the follow-up, 15 of 39 controls (38%, 23.4 to 55.4, 95%
CI) versus 35 of 42 treated patients (83%, 68.6 to 93.0, 95% CI)
had either a complete or a partial remission. The probability of
having a remission as a first event at 10 years was significantly
higher (P 0.0000) in treated patients than in controls (Fig. 3).
At univariate analysis among the considered factors (sex, age,
treatment, duration of disease, glomerular stage, vascular lesions,
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Fig. 1. Cumulative probability of survival without dialysis in patients who
received treatment (- - -) and in untreated controls (—). The difference is
significant (P = 0.0038).
1602 Ponticelli et a!: Therapy for membranous nephropathy
1.2
I
E
a)
a)0
CD
E
0.4
0.2
0
0.8
0.6
100
80
60
40
20
12 24 36 48 60 72 84 96 108 120
Time, months
Fig. 3. Probability of complete or partial remission of the nephrotic syn-
drome as a first event in the treated group (- -
-) and in control group (—).
The difference between the two curves is statistically significant (P =
0.0000).
tubulointerstitial lesions, hypertension, plasma creatinine higher
or lower than 1 mgldl, proteinuria higher or lower than 5 g per
day) only the treatment was significantly associated with the
probability of obtaining a remission (P = 0.0000).
In the treated group four patients who attained complete (1
patient) or partial remission (3 patients) were retreated after two
to three years because of relapse. All patients showed the same
clinical response (1 complete and 3 partial remissions) that lasted
Table 1. Clinical status at the last follow-up visit
Treated
patients
Untreated
patients
Total 42 39
Complete remission 17 (5) 2
Partial remission 9 (1) 11(1)
Nephrotic syndrome 9 (3) 6 (6)
Renal dysfunction 4 8 (3)
Dialysis 2 9
Death 1 3
In brackets are the patients lost to follow up and their clinical status at
the last visit. For the definitions see Methods.
for the overall follow-up except for one patient who had a second
relapse after partial remission.
Patients assigned to receive therapy spent significantly longer
time without nephrotic syndrome than untreated patients (58% of
the total follow-up period, SD 46.9 median 57.0%, vs. 22%,
37.0 median 0%; P = 0.0001). At the last follow-up visit 26 of 42
(61.9%, 45.6 to 76.4, 95% CI) treated patients were in remission
either completely (17 patients) or partially (9 patients), while only
13 of 39 untreated controls (33.3%, 19.1 to 50.2, 95% CI) were in
remission of the nephrotic syndrome (complete in 2 patients and
partial in 11; Table 1).
Side effects
Four patients assigned to methylprednisolone and chlorambutil
had to stop therapy between the third and the fifth month because
of side-effects (two peptic ulcers, one pneumonitis, one gastric
intolerance to chlorambucil). All the four patients completely
recovered from side effects with adequate therapeutic measures.
During treatment, two other patients had moderate leukopenia,
two experienced tremors, two cramps and one anxiety. Two
patients had gastric pain during chlorambucil and one developed
an increase in serum transaminases. All these side-effects reversed
after treatment was completed. In the long-term one patient
Fig. 2. Slope of the mean reciprocal of plasma
creatinine in 31 treated patients (—Ar----) and in
25 untreated controls (—U—) followed for 10
years. °P < 0.05 compared to the basal value.
12 24 36 48 60 72 84 96 108 120 *P < 0.01 compared to the basal value. The
difference between the two slopes is also
Time, months statistically significant (P = 0.035).
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developed obesity and another patient developed diabetes melli-
tus four years after treatment. No other side effects were reported
in the long-term follow-up.
Discussion
In this controlled study, the 10-year survival probability with a
functioning kidney was 0.60 in patients who never received any
specific treatment. These patients spent almost 80% of their time
with a nephrotic syndrome, and about 2/3 of untreated patients
who survived without dialysis were still nephrotic at the last
follow-up visit. The outcome was considerably different in patients
who received methylprednisolone and chlorambucil. The 10-year
survival probability with functioning kidney was 0.92, significantly
better than that observed in the untreated group. The slope of the
reciprocal of plasma creatinine remained stable in the treated
group up to 90 months, then reduced but the decline was
significantly slower than that observed in the untreated controls.
Moreover, patients given methyiprednisolone and chiorambucil
had significantly more complete or partial remissions of the
nephrotic syndrome than untreated patients. At univariate anal-
ysis the treatment was the only factor significantly associated with
remission. Looking at the whole follow-up, patients assigned to
methyiprednisolone and chlorambucil spent 58% of their time
without nephrotic syndrome and 60% of them were non-nephrotic
at the last follow-up visit. Thus, this study shows that a course of
six months with methylprednisolone and chiorambucil favors the
remission of the nephrotic syndrome and can avoid dialysis or
death within 10 years to about one third of patients with mem-
branous nephropathy and a nephrotic syndrome.
One might wonder whether these differences are due to the fact
that untreated controls had by chance a particularly bad outcome,
in spite of the homogeneous distribution at presentation of those
clinical and histological factors that may be associated with a poor
prognosis. The natural history of membranous nephropathy is
difficult to assess since it can vary according to the selection
criteria, geography, and genetic characteristics. Some studies
reported a 10-year kidney survival of 50% or less in Caucasian
patients with nephrotic syndrome [17—19]. Better results have
been reported in other series. Donadio, Torres and Velosa [20]
reported a 10-year kidney survival of 58%. Cattran et al [211 found
that the actuarial probability of maintaining normal creatinine
clearance at eight years was 60% in untreated patients. Both these
studies included a number of patients with asymptomatic protein-
uria. In spite of this, the results were not so different from the 60%
10-year kidney survival observed in our untreated nephrotic
controls. Recently Schieppati et al [22] reported a pure kidney
survival rate of 0.72 at eight years for 100 patients with membra-
nous nephropathy who never received either corticosteroids or
cytotoxic agents. They concluded that such a benign natural
course of the disease does not support the use of corticosteroids
and immunosuppressive agents. In their retrospective study 37%
of patients were non-nephrotic, the median follow-up was 39
months and deaths were excluded from the analysis. Instead in
our controlled trial all patients had a nephrotic syndrome, the
follow-up was considerably longer, and deaths were considered in
the calculation. Even with these penalties the survival rate with
kidney functioning of our untreated controls was 0.70 at eight
years, meaning that they fared at least as well as the untreated
patients reported by Schieppati et a! [22]. Thus, in spite of the
favorable natural course observed in our untreated controls
methylprednisolone and chlorambucil significantly increased the
probabilities of surviving without dialysis at 10 years, and signifi-
cantly improved the chances of attaining remission.
A main concern with the use of our protocol is the possible
developement of iatrogenic complications. Some 10% of patients
had to stop treatment because of side effects which completely
reversed after discontinuation of therapy. Theoretically chloram-
bucil may expose to neoplasia, particularly acute leukemia. This
severe complication appears to be related to high cumulative
doses, to a long duration of treatment [23, 24], and to the nature
of the disease, being more frequent in patients with cancer [25] or
polycytemia vera [261 which is considered to be a pre-leukemic
condition. We did not see any case of leukemia in this series. We
observed one case of lung cancer which developed in a heavy
smoker a few months after randomization. We cannot exclude
that membranous nephropathy was secondary to a pre-existing
cancer in this patient, since it is well known that membranous
nephropathy can be associated with cancer [27], and can often
precede the diagnosis of cancer of months or even years [28].
Reprint requests to Dr. Claudio Ponticelli, Divisione di Nefrologia e Dialisi,
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